RedHill Biopharma Files 2023 Results 6-K

TL;DR

RHBP filed its 2023 year-end results, check the 6-K for details.

AI Summary

RedHill Biopharma Ltd. filed a Form 6-K on April 8, 2024, to report its full-year 2023 financial results. The filing is a report of a foreign private issuer and indicates that the company files annual reports under Form 20-F. No specific financial figures or operational details were provided in the excerpt.

Why It Matters

This filing provides an update on RedHill Biopharma's financial performance for the full year 2023, which is crucial for investors to assess the company's financial health and strategic direction.

Risk Assessment

Risk Level: medium — As a biopharmaceutical company, RedHill Biopharma faces inherent risks related to drug development, regulatory approvals, and market competition, which are not detailed in this specific filing but are typical for the industry.

Key Players & Entities

• RedHill Biopharma Ltd. (company) — Registrant
• 001-35773 (company) — SEC File Number
• 20240408 (date) — Filing Date

FAQ

Key Financial Figures

• $6.5 million — mercial operations -- Cash balance of $6.5 million as of December 31, 2023 1 ; Gross profi
• $3.1 million — f December 31, 2023 1 ; Gross profit of $3.1 million on revenues of $6.5 million and an oper
• $12.6 million — $6.5 million and an operating income of $12.6 million during the year ended December 31, 2023
• $42.8 million — mber 31, 2023, versus operating loss of $42.8 million during the year ended December 31, 2022
• $6.5 m — the year ended December 31, 2023, were $6.5 million, compared to $61.8 million for th
• $61.8 million — 1, 2023, were $6.5 million, compared to $61.8 million for the year ended December 31, 2022. T
• $8.8 million — r ended December 31, 2023, increased to $8.8 million from $7.7 million for the year ended De
• $7.7 million — 1, 2023, increased to $8.8 million from $7.7 million for the year ended December 31, 2022, d
• $2.6 — ded December 31, 2023, were reduced by ($2.6) million in contra-revenues for Movanti
• $3.5 m — r the year ended December 31, 2023, was $3.5 million, compared to $33.3 million for th
• $33.3 million — 31, 2023, was $3.5 million, compared to $33.3 million for the year ended December 31, 2022. T
• $3.1 m — r the year ended December 31, 2023, was $3.1 million, compared to $28.5 million for th
• $28.5 million — 31, 2023, was $3.1 million, compared to $28.5 million for the year ended December 31, 2022, i
• $7.3 million — 2023, were $3.5 million, as compared to $7.3 million for the year ended December 31, 2022. T
• $31.0 m — the year ended December 31, 2023, were $31.0 million, as compared to $64.0 million for

Filing Documents

• zk2431256.htm (6-K) — 309KB
• image00001.jpg (GRAPHIC) — 293KB
• 0001178913-24-001247.txt ( ) — 713KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REDHILL BIOPHARMA LTD. (the "Registrant") Date: April 8, 2024 By: /s/ Dror Ben-Asher Name: Dror Ben-Asher Title: Chief Executive Officer Press Release RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights RedHill continues corporate transformation to focus on U.S. government-funded pipeline development in underserved, sizeable therapeutic areas with a disciplined cost-base -- Focused externally funded R&D: Opaganib for nuclear and chemical medical countermeasure (NIH funding): Selected for evaluation by two U.S. government countermeasures programs for Acute Radiation Syndrome (ARS) and Sulfur Mustard exposure. Nuclear and chemical incident response strategies are characterized by significant government stockpiling of approved agents Opaganib for Ebola (U.S. Army funding): U.S. Army studies suggest opaganib is the first host-directed molecule to show activity in vivo in Ebola virus disease, delivering a statistically significant increase in survival; separately, opaganib demonstrated robust synergistic effect in vitro when combined with remdesivir (Veklury; Gilead Sciences, Inc.), improving viral inhibition while maintaining cell viability RHB-107 for COVID-19 (U.S. DoD funding): Selected for inclusion in the 300-patient ACESO PROTECT platform trial for early COVID-19 outpatient treatment; COVID-19 treatment continues to be a multi-hundreds of million-dollar market RHB-107 for Ebola (U.S. Army funding): RHB-107 also demonstrated robust synergistic effect in vitro when combined with remdesivir. Management of potential Ebola virus pandemic outbreaks represents a significant opportunity and is a key concern for global health agencies With multiple target indications, opaganib and RHB-107 are novel, oral, host-directed small

Forward Looking Statements

Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words and include statements regarding the potential divestment of certain of our assets and/or commercial operations, progress of the R&D activities for opaganib and RHB-107, including timing of opaganib's development for Acute Radiation Syndrome and the potential market opportunity for opaganib and RHB-107. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking Nasdaq, the risk that the potential divestment of certain of our assets and/or commercial operations will not occur or will be delayed, the risk of delay in the R&D activities for opaganib or RHB-107, including the ACESO PROTECT platform trial for early COVID-19 outpatient treatment, the risk that opaganib or RHB-107 are not found to be well-suited to counter nuclear/chemical exposure and viral pandemic scenarios, risk that acceptance onto the RNCP Product Development Pipeline will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's p

View Full Filing

View this 6-K filing on SEC EDGAR